Liver Research Unit, Linkou Medical Center, Chang Gung Memorial Hospital; College of Medicine, Chang Gung University.
The optimal duration of nucelos(t)ide analoge (Nuc) treatment in hepatitis B e antigen (HBeAg) negative patients with chronic hepatitis B virus (HBV) infection is unknown. Asian Pacific Association for the Study of the Liver (APASL) guidelines recommend that treatment can be discontinued if undetectable HBV-DNA has been documented on three occasions ? 6 months apart. This study aimed to test this stopping rule in HBeAg-negative chronic hepatitis B (CHB) patients treated with Entecavir (ETV). Ninety-five patients (39 cirrhotics) were treated with ETV for a median of 721 (395-1762) days before stopping therapy and were then monitored with serum HBV DNA and alanine aminotransferase (ALT) at least every 3 months. Within 1-year after stopping ETV therapy, "clinical relapse" (an episode of ALT elevation >2× upper limit of normal plus HBV- DNA>2000IU/mL) occurred in 43 (45.3%) of the 95 patients. Of the 39 cirrhotic patients, 17 (43.6%) relapsed and one (2.6%) developed decompensation. The median duration till relapse was 230 days (74.4% > 6 months). Logistic regression analysis showed that baseline HBV-DNA ?2×10^5 IU/mL was the only significant independent factor for sustained response. The 1-year relapse rate was 29% in patients with a baseline HBV DNA ?2×10^5 IU/mL vs 53% in those with HBV DNA >2×10^5 IU/mL (p=0.027). For the later, consolidation therapy > 64 weeks reduced relapse rate to 33.3% in non-cirrhotic patients. Conclusion: With an overall 1-year relapse rate of 45% and 29% in those with a baseline serum HBV DNA ?2×10^5 IU/mL, the APASL stopping rule for HBeAg-negative CHB patients with proper off-therapy monitoring is adequate even in cirrhotic patients. Consolidation therapy > 64 weeks seems more appropriate for those with higher baseline HBV DNA. (HEPATOLOGY 2013.).
resistance is the right word, mutations accumulate anyway all the time.
i think all the study is just supposition and not a good study at all.
to say no resistance you need ultradeep sequence, the normal resistance tests are too weak sensibility and detect mutations only when most population has the mutant, let s say more than 20%, plus to see this you need years
to me it is just a clinical report with observations with weak tests and too short time which can be considered within china but not in western countries.
guidelines for hbeag neg have the goal of hbsag seroconversion now they dont even consider a stopping for nucs
After stopping etv, I relapsed after 1yr. Now im on tdf and was told by my dr I need to be on tdf forever till hbs seroconversion (which is almost like impossible I know). So he said the other chance I can give myself is to add on peg after 1-2yrs und. But this is just a 30% chance he said.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.